Marshall University

Marshall Digital Scholar
Pharmacology, Physiology and Toxicology

Faculty Research

4-30-2019

Transplanted adult human hepatic stem/progenitor cells prevent
histogenesis of advanced hepatic fibrosis in mice induced by
carbon tetrachloride
Yanzhen Bi
Xiyu Liu
Chuanping Si
Ye Hong
Yongke Lu

See next page for additional authors

Follow this and additional works at: https://mds.marshall.edu/sm_ppt
Part of the Chemical and Pharmacologic Phenomena Commons, and the Hepatology Commons

Authors
Yanzhen Bi, Xiyu Liu, Chuanping Si, Ye Hong, Yongke Lu, Pengfei Gao, Yonghong Yang, Xiaobei Zhang,
Yibo Wang, Huabao Xiong, Zhongping Duan, Yu Chen, and Feng Hong

Am J Transl Res 2019;11(4):2350-2358
www.ajtr.org /ISSN:1943-8141/AJTR0090006

Original Article
Transplanted adult human hepatic stem/progenitor
cells prevent histogenesis of advanced hepatic
fibrosis in mice induced by carbon tetrachloride
Yanzhen Bi1,2*, Xiyu Liu3*, Chuanping Si4, Ye Hong5, Yongke Lu6, Pengfei Gao7, Yonghong Yang4, Xiaobei
Zhang4, Yibo Wang4, Huabao Xiong8, Zhongping Duan1,2, Yu Chen1,2, Feng Hong4
Difficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical
University, Beijing 100069, China; 2Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment
Research, Beijing 100069, China; 3The Thoracic Surgery Department, Affiliated Hospital of Guilin Medical
University, Guilin 541001, China; 4Institute of Liver Diseases, Affiliated Hospital of Jining Medical University, Jining
272000, China; 5University of Turku, Turku 20014, Finland; 6Department of Health Sciences, College of Public
Health, East Tennessee State University, Johnson 37614, TN, USA; 7College of Pharmacy, Dali University, Dali
671000, China; 8Department of Medicine, Precision Immunology Institute, Icahn School of Medicine at Mount
Sinai, New York, NY 10029, USA. *Equal contributors.
1

Received December 17, 2018; Accepted February 24, 2019; Epub April 15, 2019; Published April 30, 2019
Abstract: Transplantation of adult human hepatic stem/progenitor cells (hHSPCs) has been considered as an alternative therapy, replacing donor liver transplantation to treat liver cirrhosis. This study assessed the antifibrotic
effects of hHSPCs in mice with fibrosis induced by carbon tetrachloride (CCl4) and examined the actions of hHSPCs
on the fibrogenic activity of human hepatic stellate cells (HSCs) in a coculture system. Isolated hHSPCs expressed
stem/progenitor cell phenotypic markers. Mice were given CCl4 (twice weekly for 7 weeks) and hHSPC transplantation weekly. CCl4 induced advanced fibrosis (bridging fibrosis and cirrhosis) in mice, which was prevented by hHSPC
transplantation. The liver of hHSPC-transplanted mice showed only occasional short septa and focal parenchymal
fibrosis, and a 50% reduction in hepatic collagen, assessed by Sirius red stain histomorphometry. Moreover, the proteins for α-smooth muscle actin (α-SMA) and collagen I were decreased. While α-SMA, collagen α1(I), and tissue inhibitor of metalloproproteinase-1 mRNAs were decreased, matrix metalloproteinase (MMP)-1 mRNA was increased,
consistent with decreased fibrogenesis. MMP-2 and transforming growth factor-β were not affected. Alanine aminotransferase and aspartate aminotransferase were lower, suggesting improvement of liver function/damage. In
coculture, hHSPCs elicited changes of α-SMA and fibrogenic molecules in HSCs similar to those observed in vivo,
providing evidence for a functional link between hHSPCs and HSCs. A decreased HSC proliferation was noted. Thus,
transplantation of hHSPCs prevents histogenesis of advanced liver fibrosis caused by CCl4. hHSPCs mediate downregulation of HSC activation coincident with modulation of fibrogenic molecule expression, leading to suppression
of fibrogenesis both in vivo and in vitro.
Keywords: Adult human hepatic stem/progenitor cells, cell transplantation, hepatic fibrosis

Introduction
Hepatic fibrosis is a chronic liver disease that
results from wound healing in response to liver
injury. The fibrosis will progress to cirrhosis, the
end stage of liver fibrotic disease. Cirrhosis
affects hundreds of millions of people worldwide and causes over 1 million deaths annually
[1]. In the US, there are 17000 adults and children awaiting liver transplantation (Data from
American Liver Foundation). Every year more
than 1500 people die waiting for a donor liver

to become available. Currently, orthotopic liver
transplantation is the only treatment that improves the survival rate in patients with live cirrhosis [2, 3]. Unfortunately, the availability of
liver transplantation is limited due to the shortage of donor livers, serious complications, immunological suppression and high costs. Therefore, searching for an effective alternative
treatment for advanced liver fibrosis is essential. Cell therapy using hepatocyte transplantation presents a promising alternative to donor
liver transplant in patients with metabolic dis-
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eases as well as acute and chronic liver failure
[3, 4]. However, the supply of viable hepatocytes is limited by the shortage of liver donors
and their low proliferative rate both in vitro and
in vivo [3, 5]. Because of their great capacity to
proliferate and ability to differentiate into mature hepatocytes, human hepatic stem/progenitor cells (hHSPCs) from adult liver [6] that
reside in the canals of Hering [7] may have
potential therapeutic effects against end-stage
liver cirrhosis.
Accordingly, in the present study we undertook
to assess the antifibrotic effects of adult
hHSPCs in experimental fibrosis in vivo and in
vitro. We first assessed the effects of hHSPC
transplantation on the histogenesis of advanced fibrosis, including bridging fibrosis and
cirrhosis, in the carbon tetrachloride (CCl4)
mouse model of fibrosis, and then examined
the actions of hHSPCs on the fibrogenic activity
of hepatic stellate cells (HSCs)-the principal
extracellular matrix producing of the liver [8] in
a co-culture system. The ultimate goal is to
establish a preclinical model of adult hHSPC
transplantation therapy for hepatic fibrosis that
could be translated into clinical medicine.
Materials and methods
Induction of hepatic fibrosis in mice by CCI4
Male C57BL6 mice weighing 22-25 g (purchased from Beijing Weitong Lihua Company,
China) were maintained according to National
Institute of Health guidelines for the care and
use of animals, approved by the Institutional
Animal Care and Use Committee of Jining
Medical University Affiliated Hospital. Mice were kept in the Animal Care Facility of Jining
Medical University with a 12-h light-dark cycle
at constant temperature. Mice had free access
to tap water during the study period. Mice were
divided into 2 groups with 10 per group. They
were administered CCl4 intraperitoneally (IP) at
a dose of 0.3 ml/kg in olive oil twice a week for
7 weeks. For cell transplantation, the CCl4-mice
were given IP either phosphate buffer saline
(PBS) or 2 × 106 hHSPCs (infra vide), weekly for
7 weeks. The mice tolerated the treatments
well and no overt adverse effects were observed. At the time of sacrifice, blood was collected in EDTA containing microfuge tubes and
pelleted at 5,000 rpm for 10 min. Serum samples were obtained for alanine aminotrans-
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ferase (ALT) and aspartate aminotransferase
(AST) measurement. Liver was removed and
divided into portions as follows: formalin fixation for Sirius red staining for collagens; snap
frozen in liquid nitrogen for mRNA extraction;
and homogenization in protein buffer for protein analysis by Western blotting.
Sirius red stain for collagens and histomorphometry of hepatic fibrosis
Liver tissue was fixed in 10% formalin, embedded in paraffin and sectioned according to the
standard methods. The sections were stained
for collagens-histological marker of fibrosiswith 0.1% Sirius red and 0.01% fast green in
saturated picric acid (Sigma-Aldrich, St. Louis,
MO, USA). Three Sirius red-stained sections
from each mouse were used for histological
evaluation of fibrosis. In each section, six images of the liver lobules were taken at a magnification of × 100, providing a total of 18 images
per animal. These were used for collagen quantification by histomorphometry using a computerized Bioquant Life Science® morphometry
system.
Isolation of human HSCs
Wedge sections of normal human live in selected patients undergoing hepatic resection for
primary benign tumors or for a single metastasis from colon cancer were used as a source of HSCs. Cells were isolated as a previously
described [9]. Immediately after hepatectomy,
a piece of liver tissue was placed in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA, USA). The liver was washed and
an intrahepatic vein cannulated for in situ
digestion with collagenase B and pronase (Roche Applied Science, Indianapolis, IN, USA). The
digested liver was subject to density gradient
centrifugation to separate the HSC fraction.
The cells were collected and plated on a plastic dish for culturing, designated as primary
human HSCs. The protocol was approved by
the Human Ethics Committee at Jining Medical
University Affiliated Hospital. Informed consents were obtained from the guardians.
Isolation and culture of hHSPCs
Isolation of hHSPCs was performed as follows:
Human liver specimens (20 to 50 g) which was
obtained from Jining Medical University Affi-
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Table 1. SYBR Green Real-Time Quantitative PCR Primer Sequences
Target gene
TGF-β
α-SMA
Collagen Iα1
TIMP-1
MMP-1
MMP-2
GADPH
AFP
CK7
CK8
CK19
ALB
MMP-13*

Forward primer
5’-CAAGGGCTACCATGCCAACT-3’
5’-GTCCCAGACATCAGGGAGTAA-3’
5’-GGCTTCCCTGGTCTTCCTGG-3’
5’-GTGGGAAATGCCGCAGAT-3’
5’-CTGGCCACAACTGCCAAATG-3’
5’-CCCCAAGCTCATCGCAGAT-3’
5’-TTCACCACCATGGAGAAGGC-3’
5’-GCAAAGCTGAAAATGCAGTTGA-3’
5’-TGAATGATGAGATCAACTTCCTCAG-3’
5’-TCATAGACAAGGTACGGTTCC-3’
5’-TCGACAACGCCCGTCTG-3’
5’-CTGAGCAAAGGCAATCAACA-3’
5’-AAGATGTGGAGTGCCTGATG-3’

Reverse primer
5’-AGGGCCAGGACCTTGCTG-3’
5’-CAGCACCGCCTGGATAGCC-3’
5’-CCAGGGGGTCCAGCCAAT-3’
5’-TGATGTGCAAGAGTCCACC-3’
5’-CTGTCCCTGAACAGCCCAGTACTTA-3’
5’-CTTGTTGCCCAGGAAAGTGAAG-3’
5’-GGCATGGACTGTGGTCATGA-3’
5’-GGAAAGTTCGGGTCCCAAAA-3’
5’-TGTCGGAGATCTGGGACTGC-3’
5’-GCCTAAGGTTGTTGATGTAGC-3’
5’-CCACGCTCATGCGCAG-3’
5’-CACAGTCTGCTGAGGTTGGA-3’
5’-AAGGCCTTCTCCACTTCAGA-3’

*mouse gene.

liated Hospital were first perfused in situ for 10
minutes with 200 to 300 mL of EGTA buffer and
collagenase type IV (0.05%) in DMEM until the
tissue became soft and showed signs of dissolution. The tissue was minced and the cell suspension was centrifuged twice at 50 × g for 2
min at 4°C. The supernatant was collected and
centrifuged at 150 × g for 8 min at 4°C. The
resultant cell pellet was resuspended in DMEM
and centrifuged at 150 × g for 5 min at 4°C.
Finally, the pelleted cells containing crude
hHSPCs were suspended in PBS for purification in density gradients made of 50% Percoll
(Sigma-Aldrich), 20% Percoll and cell suspension. The preparation was centrifuged at 350 ×
g for 20 min at 4°C. The interface between the
20% and 50% Percoll was decanted to a tube
and centrifuged at 350 × g for 5 min. The purified hHSPCs were collected and used for culture in 6-well plates in DMEM supplemented
with 10% FBS, 100 U/ml penicillin and 100
μg/ml streptomycin. These were cultured for
2-3 weeks with the medium changed twice a
week. When colonies became visible, they were
encircled with cloning rings and subcultured
to an individual well of a 6-well plate. The expanded cells were taken for assessment of
markers of hepatic stem cells. Thereafter, cells
were transferred to T-75 flasks. At confluence,
cells were taken for experiments.
Co-culture of hHSPCs and human HSCs
This was performed in 6-wells plates with transwell inserts containing microporous membrane (3 μm pore; Falcon, Becton Dickinson,
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NJ, USA). Primary human HSCs (50,000 cells/
well) were seeded into the wells of the plates
(lower compartments), while hHSPCs were seeded into the transwell inserts (upper compartments) at either 16,000 cells or 150,000 cells
in a 1/3 or 3/1 proportion relative to HSCs,
respectively. hHSPCs and HSCs were co-incubated at 37°C in a 5% CO2-air humidified atmosphere. For controls, HEK-293 cells (human
embryonic kidney cells) were used in place of
hHSPCs in the co-culture protocol. The experiments were conducted in triplicates. After cocultured for 24 hr and 48 hr, HSCs were taken
for qRT-PCR (quantitative Real Time-Polymerase Chain Reaction), Western blot analyses
and cell proliferation measurement.
RT-PCR
Total RNA was extracted from 50 mg of the
mouse liver and primary human HSCs that had
been co-cultured with hHSPCs as described
above. The RNAs were purified using an RNeasy
Mini kit (Qiagen, Valencia, CA, USA). RNA (3 µg)
was reverse transcribed into cDNA using SprintTM RT Complete-RNA to cDNA EcoDryTM
Premix (Double Primed) tubes (Clontech, Mountain View, CA, USA) and analyzed in triplicate
by qRT-PCR using SYBR green qPCR Master
Mix (Roche Applied Science) on the LightCycler
480 Real-Time PCR System (Roche Applied).
Data are presented as the relative expression
of fibrogenic genes after normalized to GAPDH. The sequences for the primers are listed in
Table 1.
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ously described [9]. hHSPCs
or HEK 293 cells (as control)
were seeded into the upper
compartments of the transwell inserts (upper compartments) and primary human
HSCs were plated (20,000
cells per well) in the lower
compartments of 24-wells
plates. hHSPCs or HEK 293
cells were co-incubated with
HSCs at 1:3 and 3:1 proportions for 24 and 48 hours.
Then, 1 μCi/mL 3H-thymidine
(specific activity 6.7 Ci/mmoFigure 1. Phase contrast microscopy (A, B) and expression of hepatocyte
and biliary epithelial cell markers (C, D) of hHSPCs. (A) During the first 10-20
le; PerkinElmer, Waltham, MA,
days in culture, the cells that are attached on the dish occur in cluster and
USA) was added to the HSC
appear round. (B) In subculture, the cells are spreading and look flattened
culture and incubated for adand larger. Original magnification 100 ×. (C) Western blots demonstrate exditional 12 hours before harpression of albumin and CK19 by hHSPCs. Upon exposure to DMSO and
HGF, albumin expression is elevated while CK19 expression is lost. (D) RTvesting. HSCs were washed
PCR shows that hHSPCs express the hepatocyte marker genes Albumin, CK8
three times with ice-cold PBS
and weakly AFP, as well as the cholangiocyte marker genes CK7 and CK19.
and fixed in methanol for 30
min at 4°C. Cells were solubiWestern blot
lized in 0.25% sodium hydroxide/0.25% sodium
dodecyl sulfate. After neutralization with hydroProteins from the mouse liver and co-cultured
chloric acid (1N), the radioactivity was meahuman primary HSCs cells were homogenized
sured in a liquid scintillation counter (Beand extracted using RIPA lysis buffer (50 mM
ckman Coulter).
Tris-HCl, pH = 8, 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate and 0.1% SDS) conStatistics
taining protease and protein phosphatase inhibitor mixtures (Roche Applied Science). The
Results are expressed as means ± standard
protein concentration was determined with a
deviation. Statistical significance between groBio-Rad DC kit (Bio-Rad, Hercules, CA, USA).
ups was tested using an unpaired Student’s
Antibodies used were as follows: rabbit antit-test (SPSS software), and P < 0.05 indicated a
collagen type I (1:3,000) (Rockland Immunosignificant difference.
chemicals, Gilbertsville, PA, USA), mouse antialpha-smooth muscle actin (αSMA) (1:500)
Results
(Millipore, Boston, MA, USA), and rabbit antiGAPDH (1:2,000) (Santa Cruz, Santas Cruz, CA,
hHSPCs phenotypes
USA).
In culture, hHSPCs that were attached on culDensitometric analysis
ture plates appeared small and round, forming
colonies at about first 15 days (Figure 1A). In
Enhanced chemiluminescent images on the
subculture, the cells looked enlarged and more
immunoblots were analyzed by scanning densiflattened, resembling hepatocytes (Figure 1B).
tometry and quantified with a BIOQUANT NOVA
These hHSPCs were found to express both
imaging system. All values were normalized to
CK19 (biliary epithelial cell marker) and albuhousekeeping protein and expressed as fold
min (hepatocyte lineage marker), as disclosed
changes relative to the controls.
by Western blotting in Figure 1C. Exposure of
the hHSPCs culture to 20 ng/ml hepatic growth
Cell proliferation assay
factor (HGF) for 5 days, followed by treatment
with 1.5% dimethyl sulfoxide (DMSO) in 10%
HSC cell proliferation was determined by incorporation of [3H]-thymidine into DNA as previfetal bovine serum (FBS) supplemented DMEM
2353
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Figure 2. A: Liver fibrosis revealed by Sirius red staining for collagens. Top row: Representative images showing the
development of advanced fibrosis induced by CCl4, which includes formation of nodules (cirrhosis) and linking septa
without apparent nodular formation (bridging fibrosis). Bottom row: Representative images showing fibrosis in mice
treated with CCl4 and were also given hHSPCs. Short septa and focal fibrotic tissue are visible. Original magnification
100 ×. B: Histomorphometry of Sirius red stained collagens. The amount of collagens in the liver parenchyma was
halved in mice received the hHSPC transplantation. N = 10 mice/group.

for an additional 5 days resulted in a loss of
CK19 expression, concomitant with an enhancement of albumin expression. These data
indicate differentiation of hHSPCs into hepatocyte-like cells in response to HGF and DMSO.
Additionally, RT-PCR analysis revealed that
hHSPCs strongly expressed hepatocyte marker
genes ALB and CK8, while weakly expressed
the gene for AFP. The cholangiocyte marker
genes CK7 and CK19 were also expressed at a
high level in hHSPCs (Figure 1D).
Anti-fibrotic effects of hHSPCs on hepatic fibrosis induced by CCI4 in mice
As revealed by Sirius red staining for collagens,
the livers of CCl4-mice receiving PBS vehicle
developed advanced fibrotic changes showing
bridging fibrous septa (bridging fibrosis), incomplete nodule formation, and complete nodule
formation (cirrhosis)-histological hallmarks of
advanced fibrosis (Figure 2A). In striking contrast, no bridging septa and nodule formation
were observed in the livers of the CCl4-mice
receiving hHSPC transplantation. In some of
these livers, there were occasional short septa
and focal parenchymal fibrosis present in the
liver lobules. Histomorphometry revealed that
the percent of Sirius red-stained collagen area
in the lobules was reduced by more than 50%
in the CCl4-mice with hHSPC transplantation
(Figure 2B).
Having demonstrated the beneficial effect of
hHSPC transplantation against the development of advanced fibrosis induced by CCl4, we
examined expression of fibrogenic molecules in
2354

the mouse liver. As shown in Figure 3A, 3B, the
protein content for α-SMA or collagen I was significantly decreased (40%) by hHSPCs transplantation into the CCl4-mice. Furthermore, the
mRNA levels for αSMA, collagen α1(I), and tissue inhibitor of metalloproteinase-1 (TIMP-1)
were significantly decreased (35%, respectively) in CCl4-mice received the hHSPCs transplantation, while the mRNA for matrix metalloproteinase (MMP)-13 was increased by 40% (Figure 3C). The mRNAs for TGFβ1 and MMP-2,
however, were not affected.
hSCPCs transplantation corrected the CCl4induced liver damage
Liver functions of mice were evaluated by measurement of plasma ALT and AST. Mice with
CCl4 plus hHSPCs transplantation had significantly lower ALT (320.6 ± 62.2 U/dl; P < 0.05, N
= 10) and slightly lower AST (295.3 ± 135.2 U/
dl) activity compared to those of mice treated
with CCl4 alone (ALT, 512.6 ± 92.3 U/dl and
AST, 503.3 ± 61.2 U/dl). These data indicate
the beneficial effect of hHSPCs transplantation
in correcting liver damage/adverse liver functions caused by CCl4.
Effects of hHSPCs on human primary HSCs in
co-culture
To test the antifibrotic actions of hHSPCs on
primary human HSCs in co-culture, we determined expression of fibrosis-related molecules
in HSCs. Figure 4A, 4B shows that hHSPCs
significantly decreased the protein levels for
Am J Transl Res 2019;11(4):2350-2358
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Figure 3. Expression of α-SMA and collagen I proteins (A, B) and changes
in mRNA levels (C) in the liver of CCl4 mice received hHSPC transplantation.
(A, B) Upper panel: Immunoblots of four mice; lower panel: corresponding
histograms of data of the blots. Both α-SMA and collagen I levels were reduced by nearly halves in the mice with the transplanted hHSPCs. Values are
expressed as fold change relative to CCl4-treated mice; N = 4 mice/group. (C)
While α-SMA, collagen α1(I) and TIMP-1 mRNA levels were downregulated,
MMP-13 mRNA level was upregulated. The gene expression for TGF-β and
MMP-2 was not altered. Values are expressed relative to CCl4-treated mice;
N = 10 mice/group.

αSMA (60%) and collagen I (50%) in HSCs.
Additionally, hHSPCs suppressed the mRNA
levels for αSMA, α1(I) collagen, and TIMP-1,
each by 30%, in human HSCs, while elevated
mRNA for MMP-1 by 23% (Figure 4C). The gene
expression for TGFβ1 and MMP-2 was not
affected.
Figure 5 shows inhibition of primary HSC proliferation by hHSPC in the co-culture system
by more than 25% at the ratio of 3:1 for
hHSPCs:HSCs for 24 h, but not at the 1/3 ratio, suggesting a dose response. Also, the inhibition of proliferation seems to be transient as
the effect disappeared in cells co-cultured for a
longer duration of 48 hr.

human bone marrow were
shown to diminish fibrosis and
ameliorate chronic liver damage in rats caused by CCl4
[11]. Infusion of human bone
marrow-derived mesenchymal
stem cells led to an improvement of CCl4-induced cirrhosis
in mice [12]. The antifibrotic effect was found to be associated with decreased expression
of αSMA, TNF-α and TGF-β
and conversely stimulation of
MMP-9. Liver fibrosis can spontaneously regress upon the
cessation of fibrogenic agents.
To that effect, transplantation
of bone marrow cells facilitates the resolution of liver fibrosis in mice, coincident with
increased expression of the
matrix protein degradation enzymes MMP-13 and MMP-9
[13]. The severity of cirrhosis
caused by CCl4 in rats was
lessened by infusion of human
umbilical cord blood-derived
mesenchymal cells, accompanied by inhibition of TGF-β1,
collagen I and α-SMA expression [14].

Transplantation of human fetal hepatic progenitor cells to a cohort of 25 patients with endstage decompensated cirrhosis demonstrated
a decrease in the Mayo’s Model for End Stage
Liver Disease (MELD) mean score in 6 months
follow-up [15]. Along this line, fetal liver stem
cells were found to contribute to the recovery of
fulminant hepatic failure in rats [16].

Discussion

Adult human hepatic stem cells were reported
to contribute to the regeneration of liver parenchyma in severe-combined immunodeficient
mice [17]. Additionally, the stem cells improved liver injury in a mouse model of fulminant
liver failure, accompanied by reduction in animal mortality, decrease in apoptosis and enhancement of liver regeneration [18].

Experimental cell-based therapy for liver fibrosis and/or liver failure has been examined
using stem cells from extrahepatic sources or
from fetal and adult livers [3, 10]. Specifically, mesenchymal stem cells derived from

It is noteworthy that the above mentioned studies were aimed at the reduction of either established cirrhosis or chronic liver injury/failure in
animal models, or treatment of end-stage cirrhosis in humans, using extrahepatic mesen-
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Figure 4. Expression of α-SMA and collagen I proteins (A, B) and changes in
mRNA levels (C) in HSCs co-cultured with hHSPCs. (A, B) Upper panel: Immunoblots of three separate cultures; lower panel: corresponding histograms
of data of the blots. Both α-SMA and collagen I levels in HSCs were reduced
by halves in the presence of hHSPCs. Values are expressed relative to the
control HEK293/HSC culture. (C) Control: HSCs were cultured alone in the
bottom compartment of the Transwell, while the upper compartment contained only the medium. Negative control: HSCs in the bottom compartment
were co-cultured HEK293 cells in the upper compartment. hHSPC: HSCs
were co-cultured with hHSPCs in the upper compartment. Gene expression
for α-SMA, collagen α1(I) and TIMP-1 in HSCs were downregulated by the
presence of hHSPCs. The mRNA level of MMP-1 was higher, while the levels
of TGF-β and MMP-2 were not altered. Values are expressed relative to HSC
control.

in the prevention of advanced
liver fibrosis development in
CCl4-mice. Admittedly, our experimental design is at variance with the protocols employing cell therapy in the treatment of established cirrhosis in either animal models or
patients in the clinical settings. Nonetheless, our study
discovered a novel action of
hHSPCs against the histogenesis of liver fibrosis to advanced stage fibrosis, namely
bridging fibrosis and cirrhosis.
The hHSPC’s antifibrotic action involves downregulation
of HSC activation and modulation of expression of critical
fibrogenic molecules that mediate the production of collagen I and hence fibrosis.

HSCs residing in the space of
Disse [19] produce the principal extracellular matrix proteins in the liver, collagen I included [8]. HSCs express αSMA, which is a phenotypic
marker of human HSCs [20].
Additionally, HSCs synthesize
MMP-1 (in humans) or MMP13 (in rodents), MMP-2, and
TIMP-I in response to soluble
signals released from profibrotic factors [21, 22]. Of these genes, α-SMA, collagen I,
MMP-2, TIMP-1 are upregulated during progressive liver fibrosgenesis and in culture-induced activation of HSCs [22].
Therefore, expression of these
transcripts is related to stellate cell activation. On the
Figure 5. Effects of hHSPCs on proliferation of HSCs. Control: HSCs were
other hand, MMP-1 mRNA excultured alone in the bottom compartment of the Transwell, while the uppression, which is reduced in
per compartment contained only the medium. Negative control: HSCs coliver fibrosis, is enhanced in
cultured with HEK293 cells. hHSPCs: hHSPCs were co-cultured with HSCs.
hHSPCs when co-cultured with HSCs at the ratio of 3/1 elicited a 25% inhibiearly primary HSC culture but
tion of HSC proliferation. Values are expressed relative to HSC control.
then decreases in late culture.
Thus, MMP-1 expression is
chymal cells, or fetal and adult liver stem cells.
associated with downregulation of stellate cell
activation phenotype, coincident with deIn the present study, we sought to test the efficreased fibrogenic activity. Notably, the activity
cacy of hHPSCs derived from adult human liver
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of MMP-1 is regulated by TIMP-1, its physiological inhibitor. As a result, collagen deposition in
liver fibrosis is the outcome of an imbalance
between the production of MMP-1 and its inhibitor TIMP-1 [23].
Our study showed that transplantation of hHSPCs prevents the development of advanced
fibrosis (bridging fibrosis and cirrhosis) in CCl4mice. Instead, the liver of hHSPC-transplanted
mice displays only occasional short septa and
sporadic focal fibrotic tissue. The histopathology was corroborated by histomorphometry,
revealing a greater than 50% reduction in the
amount of collagen deposition in the liver of
CCl4-mice received the transplanted hHSPCs.
Additionally, biochemical analysis disclosed
that the hepatic α-SMA and collagen I proteins
were significantly decreased with a corresponding decrease in their gene expression. Concomitantly, gene expression for α-SMA, collagen α1(I), and TIMP-1 was suppressed while
that of MMP-13 was enhanced. The downregulation of α-SMA likely reflects the change in the
activation of HSCs to a less activated state-or a
more quiescent phenotype. Because MMP-1 is
the major proteinase that degrades collagen I
and its enzymatic activity is inhibited by TIMP-1,
the imbalanced production of MMP-1 relative
to TIMP-1 promotes the degradation of collagen
I, thereby resulting in diminished collagen deposition. These changes could explain the decrease in fibrosis in the liver with transplanted
hHSPC in vivo. We also found that the transplanted hHSPCs are beneficial in correcting the
liver damage caused by CCl4 treatment based
on the decreased values of AST and ALT.
We then tested whether hHSPCs interact with
HSCs, promoting the downregulation of the fibrogenic activities of HSCs. To that end, hHSPCs were co-cultured with HSCs in a transwell
system separated by a porous membrane filter.
We found that α-SMA expression was lowered
at both the protein and mRNA levels, indicating the acquisition of a phenotype with a diminished fibrogenic activity. Consequently, the
levels collagen I mRNA level and protein were
both decreased, coincident with increased expression of MMP-1 while decreasing that of
TIMP-1. The changes are consistent with findings in vivo (vide supra) and provide an explanation for the suppressed fibrogenesis at the cellular level, i.e. HSCs.
TGF-β and MMP-2 are known to involve in the
development of liver fibrosis [24]. However, our
2357

data did not show that the expression of these
factors was altered under our experimental
conditions, suggesting that their regulation is
independent of the antifibrotic actions of hHSPCs. Our study also showed that the proliferation of HSCs in coculture with hHSPCs is inhibited although transiently. Because we did not
determine HSC proliferation in vivo, the significance of inhibition of HSC proliferation by
hHSPCs remains to be evaluated.
In conclusion, we have isolated hHSPCs from
adult human liver and characterized their stem/
progenitor cellular phenotypes. Our study documented the striking ability for transplanted
hHSPCs to prevent the histogenesis of advanced liver fibrosis in mice induced by CCl4.
The antifibrotic action of hHSPCs in vivo appears to involve downregulation of HSC activation and modulation of fibrogenic-related molecule expression, and these effects in vivo were
replicated in coculture comprising hHSPCs and
human HSCs. Thus, our in vivo and in vitro culture findings together provide evidence for a
functional link between hHSPCs and HSCs,
which could explain the antifibrotic action of the
transplanted hHSPCs. It is likely that hHSPCs
secrete soluble molecules that modulate the
fibrogenic activities of HSCs via a paracrine
mechanism. It will be our continuous efforts to
identify and characterize these paracrine factors released by hHSPCs. The current investigation is a new starting point for our goal to establish a preclinical model of adult hHSPC transplantation for therapeutic intervention of the
histogenesis of advanced hepatic fibrosis in
humans.
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